Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year's live-online...
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year's live-online...
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year's live-online...
We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year's live-online...
For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for...
From the GRACE Archives - Originally Published August 26, 2009 | By Dr Pennell OK, I hope you all aren’t bored to tears by this topic by now, given...
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
Hello. My mom (aged 79, Stage 4, NSCLC, diagnosed 1/2014, currently on Rozlytrek) had a “Chest CT with Contrast” this week. Is it appropriate for the result to be compared to her last “PET /CT Without Contrast”? I’m concerned they’re calling possible disease progression but the comparison might not be appropriate. Please advise. Thank you.
I know that I have adenocarcinoma but doctor said also embryonic type. Can anyone explain what it is and does targeted meds for efgr mutation work on these types of tumors?
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.